Financhill
Buy
56

EDIT Quote, Financials, Valuation and Earnings

Last price:
$2.82
Seasonality move :
-16.64%
Day range:
$2.80 - $3.09
52-week range:
$0.91 - $6.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.64x
P/B ratio:
3.86x
Volume:
2.3M
Avg. volume:
3M
1-year change:
-47.35%
Market cap:
$241.1M
Revenue:
$32.3M
EPS (TTM):
-$3.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDIT
Editas Medicine
$1.8M -$0.38 251.82% -54.6% $3.38
ABUS
Arbutus Biopharma
$1.6M -$0.07 -7.67% -40.73% $5.32
AVXL
Anavex Life Sciences
-- -$0.15 -- -3.57% $34.33
BNGO
Bionano Genomics
$6.9M -$2.93 -11.23% -79.65% $7.33
MIRM
Mirum Pharmaceuticals
$107.8M -$0.34 38.47% -34.98% $68.60
SRPT
Sarepta Therapeutics
$529.8M $1.17 54.01% 1720.11% $47.96
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDIT
Editas Medicine
$2.88 $3.38 $241.1M -- $0.00 0% 6.64x
ABUS
Arbutus Biopharma
$3.17 $5.32 $607.1M -- $0.00 0% 93.75x
AVXL
Anavex Life Sciences
$11.11 $34.33 $948.5M -- $0.00 0% --
BNGO
Bionano Genomics
$3.40 $7.33 $11.4M -- $0.00 0% 0.17x
MIRM
Mirum Pharmaceuticals
$52.66 $68.60 $2.6B -- $0.00 0% 7.31x
SRPT
Sarepta Therapeutics
$18.17 $47.96 $1.8B 20.50x $0.00 0% 0.90x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDIT
Editas Medicine
-- 1.732 -- 3.03x
ABUS
Arbutus Biopharma
-- -0.704 -- 5.86x
AVXL
Anavex Life Sciences
-- 0.090 -- --
BNGO
Bionano Genomics
21.3% -0.373 150.7% 0.82x
MIRM
Mirum Pharmaceuticals
56.95% 1.968 13.85% 2.93x
SRPT
Sarepta Therapeutics
49.9% -0.560 18.15% 2.06x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDIT
Editas Medicine
-- -$35.3M -139.77% -139.77% -1585.92% -$47.9M
ABUS
Arbutus Biopharma
-- -$13M -73.56% -73.56% -1388.78% -$13.4M
AVXL
Anavex Life Sciences
-- -$12.4M -- -- -- -$5.9M
BNGO
Bionano Genomics
$2.9M -$8.5M -112.51% -141.6% -46.62% -$2.8M
MIRM
Mirum Pharmaceuticals
$88.6M -$15.2M -14.36% -33.5% -9.01% -$2M
SRPT
Sarepta Therapeutics
$607.3M -$300.4M -10.44% -20.94% -50.88% -$629.3M

Editas Medicine vs. Competitors

  • Which has Higher Returns EDIT or ABUS?

    Arbutus Biopharma has a net margin of -1633.49% compared to Editas Medicine's net margin of -1390.36%. Editas Medicine's return on equity of -139.77% beat Arbutus Biopharma's return on equity of -73.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDIT
    Editas Medicine
    -- -$0.92 $62.4M
    ABUS
    Arbutus Biopharma
    -- -$0.13 $79.2M
  • What do Analysts Say About EDIT or ABUS?

    Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 17.19%. On the other hand Arbutus Biopharma has an analysts' consensus of $5.32 which suggests that it could grow by 67.85%. Given that Arbutus Biopharma has higher upside potential than Editas Medicine, analysts believe Arbutus Biopharma is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDIT
    Editas Medicine
    4 8 0
    ABUS
    Arbutus Biopharma
    2 1 0
  • Is EDIT or ABUS More Risky?

    Editas Medicine has a beta of 2.155, which suggesting that the stock is 115.489% more volatile than S&P 500. In comparison Arbutus Biopharma has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.835%.

  • Which is a Better Dividend Stock EDIT or ABUS?

    Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arbutus Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Arbutus Biopharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDIT or ABUS?

    Editas Medicine quarterly revenues are $4.7M, which are larger than Arbutus Biopharma quarterly revenues of $1.8M. Editas Medicine's net income of -$76.1M is lower than Arbutus Biopharma's net income of -$24.5M. Notably, Editas Medicine's price-to-earnings ratio is -- while Arbutus Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 6.64x versus 93.75x for Arbutus Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDIT
    Editas Medicine
    6.64x -- $4.7M -$76.1M
    ABUS
    Arbutus Biopharma
    93.75x -- $1.8M -$24.5M
  • Which has Higher Returns EDIT or AVXL?

    Anavex Life Sciences has a net margin of -1633.49% compared to Editas Medicine's net margin of --. Editas Medicine's return on equity of -139.77% beat Anavex Life Sciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDIT
    Editas Medicine
    -- -$0.92 $62.4M
    AVXL
    Anavex Life Sciences
    -- -$0.13 --
  • What do Analysts Say About EDIT or AVXL?

    Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 17.19%. On the other hand Anavex Life Sciences has an analysts' consensus of $34.33 which suggests that it could grow by 209.03%. Given that Anavex Life Sciences has higher upside potential than Editas Medicine, analysts believe Anavex Life Sciences is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDIT
    Editas Medicine
    4 8 0
    AVXL
    Anavex Life Sciences
    2 0 0
  • Is EDIT or AVXL More Risky?

    Editas Medicine has a beta of 2.155, which suggesting that the stock is 115.489% more volatile than S&P 500. In comparison Anavex Life Sciences has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.343%.

  • Which is a Better Dividend Stock EDIT or AVXL?

    Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Anavex Life Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDIT or AVXL?

    Editas Medicine quarterly revenues are $4.7M, which are larger than Anavex Life Sciences quarterly revenues of --. Editas Medicine's net income of -$76.1M is lower than Anavex Life Sciences's net income of -$11.2M. Notably, Editas Medicine's price-to-earnings ratio is -- while Anavex Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 6.64x versus -- for Anavex Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDIT
    Editas Medicine
    6.64x -- $4.7M -$76.1M
    AVXL
    Anavex Life Sciences
    -- -- -- -$11.2M
  • Which has Higher Returns EDIT or BNGO?

    Bionano Genomics has a net margin of -1633.49% compared to Editas Medicine's net margin of -48.04%. Editas Medicine's return on equity of -139.77% beat Bionano Genomics's return on equity of -141.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDIT
    Editas Medicine
    -- -$0.92 $62.4M
    BNGO
    Bionano Genomics
    45.5% -$1.15 $61.2M
  • What do Analysts Say About EDIT or BNGO?

    Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 17.19%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 115.69%. Given that Bionano Genomics has higher upside potential than Editas Medicine, analysts believe Bionano Genomics is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDIT
    Editas Medicine
    4 8 0
    BNGO
    Bionano Genomics
    0 2 0
  • Is EDIT or BNGO More Risky?

    Editas Medicine has a beta of 2.155, which suggesting that the stock is 115.489% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.207, suggesting its more volatile than the S&P 500 by 120.694%.

  • Which is a Better Dividend Stock EDIT or BNGO?

    Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDIT or BNGO?

    Editas Medicine quarterly revenues are $4.7M, which are smaller than Bionano Genomics quarterly revenues of $6.5M. Editas Medicine's net income of -$76.1M is lower than Bionano Genomics's net income of -$3.1M. Notably, Editas Medicine's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 6.64x versus 0.17x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDIT
    Editas Medicine
    6.64x -- $4.7M -$76.1M
    BNGO
    Bionano Genomics
    0.17x -- $6.5M -$3.1M
  • Which has Higher Returns EDIT or MIRM?

    Mirum Pharmaceuticals has a net margin of -1633.49% compared to Editas Medicine's net margin of -13.15%. Editas Medicine's return on equity of -139.77% beat Mirum Pharmaceuticals's return on equity of -33.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDIT
    Editas Medicine
    -- -$0.92 $62.4M
    MIRM
    Mirum Pharmaceuticals
    79.37% -$0.30 $541.8M
  • What do Analysts Say About EDIT or MIRM?

    Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 17.19%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of $68.60 which suggests that it could grow by 30.27%. Given that Mirum Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe Mirum Pharmaceuticals is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDIT
    Editas Medicine
    4 8 0
    MIRM
    Mirum Pharmaceuticals
    6 0 0
  • Is EDIT or MIRM More Risky?

    Editas Medicine has a beta of 2.155, which suggesting that the stock is 115.489% more volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.179%.

  • Which is a Better Dividend Stock EDIT or MIRM?

    Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDIT or MIRM?

    Editas Medicine quarterly revenues are $4.7M, which are smaller than Mirum Pharmaceuticals quarterly revenues of $111.6M. Editas Medicine's net income of -$76.1M is lower than Mirum Pharmaceuticals's net income of -$14.7M. Notably, Editas Medicine's price-to-earnings ratio is -- while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 6.64x versus 7.31x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDIT
    Editas Medicine
    6.64x -- $4.7M -$76.1M
    MIRM
    Mirum Pharmaceuticals
    7.31x -- $111.6M -$14.7M
  • Which has Higher Returns EDIT or SRPT?

    Sarepta Therapeutics has a net margin of -1633.49% compared to Editas Medicine's net margin of -60.08%. Editas Medicine's return on equity of -139.77% beat Sarepta Therapeutics's return on equity of -20.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDIT
    Editas Medicine
    -- -$0.92 $62.4M
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
  • What do Analysts Say About EDIT or SRPT?

    Editas Medicine has a consensus price target of $3.38, signalling upside risk potential of 17.19%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 163.95%. Given that Sarepta Therapeutics has higher upside potential than Editas Medicine, analysts believe Sarepta Therapeutics is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDIT
    Editas Medicine
    4 8 0
    SRPT
    Sarepta Therapeutics
    10 12 1
  • Is EDIT or SRPT More Risky?

    Editas Medicine has a beta of 2.155, which suggesting that the stock is 115.489% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

  • Which is a Better Dividend Stock EDIT or SRPT?

    Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDIT or SRPT?

    Editas Medicine quarterly revenues are $4.7M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Editas Medicine's net income of -$76.1M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Editas Medicine's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 6.64x versus 0.90x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDIT
    Editas Medicine
    6.64x -- $4.7M -$76.1M
    SRPT
    Sarepta Therapeutics
    0.90x 20.50x $744.9M -$447.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 37.98% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 24.07% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 2.66% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock